Global Pericarditis Drugs Market

The Global Pericarditis drugs market was valued $xx Mn in 2019 and is expected to reach $xx Mn in 2027, at a CAGR of xx% during the forecast period.

Pericarditis is an inflammation caused to sac-like membrane surrounding the heart i.e. pericardium. Pericarditis is usually acute and may last up to several months. The inflammation causes chest pain and accumulation of fluid around the pericardium. Other symptoms include low grade fever, increased heart rate, leg or abdominal swelling, cough and shortness of breath.
Global Pericarditis Drugs Market Dynamics:

Increasing prevalence of cardiovascular diseases and pericarditis is expected to drive the demand for pericarditis drugs. According to the study done by American heart association, the prevalence is high in men than women. Assimilation of pain management in the medicine domain, adoption of dual therapy for the treatment of pericarditis has fueled the growth of pericarditis drugs market.
Global Pericarditis Drugs Market Regional analysis:

To know about the Research Methodology :- Request Free Sample Report

North America dominates the global pericarditis drugs market.

North America held largest market share in 2019 due to high number of heart disease patients and high expenditure on R&D and healthcare. Market size in Europe was USD xx Mn. in 2019. Detailed analysis of European market in countries is given in the report with local market dynamics and healthcare opportunities for the investors.

The objective of the report is to present a comprehensive analysis of the Global Pericarditis Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Pericarditis Drugs Market dynamics, structure by analyzing the market segments and project the Global Pericarditis Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Pericarditis Drugs Market make the report investor’s guide.
Scope of Global Pericarditis Drugs Market: Inquire before buying

Global Pericarditis Drugs Market segmentation:-

Global Pericarditis Drugs Market, By drug-type:

• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Colchicine
• Others

Global Pericarditis Drugs Market1

Owing to the therapeutic benefits, NSAIDs and colchicine dominate the global pericarditis drugs market. However, NSAIDs increase the risk of cardiovascular diseases in patients owing to which the US FDA had issued warnings on the use of NSAIDs.

Global Pericarditis Drugs Market1
Global Pericarditis Drugs Market, By distribution channels:

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
Global Pericarditis Drugs Market, By disease:

• Acute pericarditis
• Chronic pericarditis
• Recurrent pericarditis
• Idiopathic pericarditis

Acute Pericarditis is the most common condition affecting the pericardium. It lasts for less than 6 weeks. Chest pain is the common symptom of acute pericarditis. Colchicine has proved essential treatment in acute pericarditis.
Key players operating in the Global Pericarditis Drugs Market:

• Cleveland Clinic
• Cigna
• AstraZeneca Plc.
• Bayer AG
• Pfizer Inc.
• Takeda Pharmaceutical co. ltd.
• XYMAX Pharmaceuticals
• Perifect
• Wockhardt
• Allergan
• Hikma pharmaceuticals
• Merck & Co. Inc
Global Pericarditis Drugs Market Competitive Landscape:

According to the news released by Cleveland clinic on 16th November 2020, researchers have found that rilonacept, an FDA approved drug for inflammatory diseases resolved acute pericarditis and reduced the risk of recurrence. This study was published in the New England Journal of Medicine and presented at the American Heart Association’s scientific sessions.

For a More Information Visit @: 

This Report Is Submitted By: Maximize Market Research Company

Customization of the report: 

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Author: Web Spangle

Leave a Reply

Your email address will not be published.